31 results
8-K
EX-99.1
GLTO
Galecto Inc
27 Jan 22
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
8:31am
Exhibit 99.1
Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients … on Standard of Care
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung
8-K
EX-99.1
GLTO
Galecto Inc
29 Sep 22
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
7:00am
of GB2064 as evaluated by the treating physician.
Professor Claire Harrison, Guy’s & St Thomas NHS Foundation Trust, and Chair of the Safety Review … endpoint of the ongoing MYLOX-1 trial is an assessment of safety and tolerability, while secondary endpoints focus on measurements of bone marrow
8-K
EX-99.1
GLTO
Galecto Inc
15 Mar 21
Regulation FD Disclosure
7:52am
Exhibit 99.1
Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic … : GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that an independent Data Safety
8-K
EX-99.1
GLTO
Galecto Inc
31 Oct 22
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022
9:00am
of its GULLIVER-2 trial (NCT05009680), an innovative, hybrid-design 3-part study investigating the safety, pharmacokinetics (PK), and exploratory … Presentation Title: Preliminary safety, pharmacokinetics, and efficacy of GB1211 in cirrhotic patients: initial findings from the GULLIVER-2 trial
8-K
EX-99.1
GLTO
Galecto Inc
5 Jan 22
Regulation FD Disclosure
4:02pm
in patients not on pirfenidone or nintedanib Key secondary outcomes: Safety, Diffusing Capacity for Carbon Monoxide (DLCO), 6-minute walk test, Quality of Life … of blinded treatment until last patient has received his/her 12-week treatment Long term safety follow-up Unblinding after the last patient has received
8-K
EX-99.1
sfwi j6w0ow713
23 Oct 23
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
9:00am
8-K
lfo5ot
15 Aug 23
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
8:00am
10-K
2c5rm2iea32dc3fbo9
29 Mar 21
Annual report
6:03am
8-K
rehyc9k
21 Dec 23
Other Events
4:30pm
8-K
nog8hmguez7vn8
29 Sep 22
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
7:00am
8-K
EX-99.1
9dlhu5dyf27x7e
5 Jan 21
Results of Operations and Financial Condition
4:31pm
8-K
EX-99.1
2pq0dc4xu
15 Aug 23
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
8:00am
DRS
pckxms pe
2 Sep 20
Draft registration statement
12:00am
424B4
cuza4n5f qm
30 Oct 20
Prospectus supplement with pricing info
4:31pm
S-1
c96ys cy1l
7 Oct 20
IPO registration
5:01pm